Orient Biotech's subsidiary has obtained registration certificates for two medical device products
Orient Biotech's subsidiary Hangzhou Danwei Biotechnology Co., Ltd. recently obtained registration certificates for two medical device products, namely the 14 types of high-risk HPV nucleic acid detection and 16/18 typing reagent kits, and the combined nucleic acid detection reagent kit for the novel coronavirus and influenza A and B viruses. The registration of these products will enrich the company's product line in the fields of HPV virus detection and respiratory virus detection, helping to expand the domestic market
According to the Zhitong Finance APP, Orient Biotech (688298.SH) announced that its controlling subsidiary Hangzhou Danwei Biotechnology Co., Ltd. (referred to as "Hangzhou Danwei") recently obtained registration certificates for two medical device products. The product names are: 14 types of high-risk human papillomavirus nucleic acid detection and 16/18 typing reagent kit (fluorescent PCR method), and a combined nucleic acid detection reagent kit for the novel coronavirus 2019-nCoV and influenza A and B viruses (fluorescent PCR method).
The registration of the aforementioned 14 types of high-risk HPV nucleic acid detection and 16/18 typing reagents in China further enriches the company's product variety for HPV virus detection; the registration of the combined nucleic acid detection reagents for COVID-19 and influenza A and B viruses in China further improves the company's layout of respiratory combined detection products in the domestic market, which is beneficial for addressing routine seasonal respiratory virus infection detection. The registration of these two products broadens the range of products that the company can sell in the domestic molecular diagnostic technology sector, facilitating overall expansion in the domestic market
